Vaginal Abnormality Clinical Trial
Official title:
Retrospective Review on Uterovaginal Anomalies
Verified date | May 2024 |
Source | Chinese University of Hong Kong |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Review of surgical outcomes of patient who have undergone surgery for uterovaginal anomalies. Case notes of patients would be reviewed and data would be gathered for statistical analysis.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | February 14, 2025 |
Est. primary completion date | February 14, 2025 |
Accepts healthy volunteers | |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - All patients who attended the Prince of Wales Hospital with the diagnosis of uterovaginal anomaly since 2000 Exclusion Criteria: - Nil |
Country | Name | City | State |
---|---|---|---|
Hong Kong | The Chinese University of Hong Kong | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Chinese University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of re-stenosis | Patient record will be reviewed. Number of patients need re-stenosis after surgical treatment for obstructive uterovaginal anomalies will be counted. | 1 year after operation | |
Primary | Incidence of re-operation | Patient record will be reviewed. Number of patients need re-operation after surgical treatment for obstructive uterovaginal anomalies will be counted. | 1 year after operation | |
Primary | Number of patients with normal menstruation after operation | Menstruation status will be reviewed in post-operation follow up. Number of patients with normal menstruation after surgical treatment for obstructive uterovaginal anomalies will be counted. | 1 year after operation | |
Primary | Number of patients with sexual intercourse after operation | Sexual status will be asked in post-operation follow up. Number of patients with sexual intercourse after surgical treatment for obstructive uterovaginal anomalies will be counted. | 1 year after operation | |
Primary | Number of patients with post-operative infection | Patient record will be reviewed. Number of patients with post-operative infection will be counted. | 1 year after operation | |
Primary | Number of patients with pregnancy after operation | Pregnancy status will be reviewed. Number of patients with ultrasound confirmed pregnancy after operation will be counted. | 1 year after operation | |
Secondary | Background demographics affecting post-operative outcomes for patients with uterovaginal anomalies | Background demographics including age at diagnosis, age at operation, difference in age between menarche and diagnosis/ operation, history of previous abdominal or reproductive tract surgery, menstrual cycle will be reviewed.
Categorical data will be analyzed with Chi square or Fisher's exact test. Continuous data will be analyzed with t test and ANOVA test. The significance level is set at 0.05. |
1 year after operation | |
Secondary | Number of participants with Pre-operative factors affecting post-operative outcomes | Pre-operative factors including presentation at diagnosis, laterality of hematocolpos, thickness and size of septum, distance of septum to perineum, obstructed longitudinal septum axis and the type of renal anomaly will be reviewed.
Categorical data will be analyzed with Chi square or Fisher's exact test. Continuous data will be analyzed with t test and ANOVA test. The significance level is set at 0.05. |
1 year after operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03185169 -
GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors
|
Early Phase 1 | |
Not yet recruiting |
NCT05381584 -
Balloon Vaginoplasty for Treatment of Vaginal-aplasia
|
N/A | |
Recruiting |
NCT05165056 -
Photobiomodulation Therapy in the Prevention and Management of Radiotherapy-induced Vaginal Toxicity
|
N/A | |
Suspended |
NCT03547089 -
A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes
|
N/A |